Sachin Mehta, MD
Ophthalmology · Phoenix, AZNPI 1619181260
Payments from drug & device makers
Across 191 payments — averaging $256.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$26K
- Alimera Sciences, Inc.$5K
- Novartis$4K
- Regeneron$3K
- Bausch & Lomb Americas Inc.$3K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- plus $6K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 8 | $25,538 |
| Alimera Sciences, Inc. | 26 | $4,894 |
| Novartis | 9 | $4,403 |
| Regeneron | 12 | $2,587 |
| Bausch & Lomb Americas Inc. | 22 | $2,573 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $2,521 |
| Cardinal Health 108 LLC | 1 | $1,575 |
| Regeneron Healthcare Solutions, Inc. | 34 | $1,146 |
| Genentech USA, Inc. | 23 | $812 |
| Notal Vision, Inc. | 2 | $585 |
| Astellas Pharma US Inc | 15 | $543 |
| Apellis Pharmaceuticals, Inc. | 7 | $369 |
| Alcon | 8 | $345 |
| Dutch Ophthalmic, USA | 2 | $233 |
| Eyevance Pharmaceuticals LLC | 1 | $171 |
| Glaukos Corporation | 1 | $132 |
| Ivantis, Inc | 1 | $109 |
| ANI Pharmaceuticals, Inc. | 4 | $78 |
| AbbVie(2 entities) | 4 | $60 |
| Harrow Eye, LLC | 2 | $54 |
| Biogen | 2 | $45 |
| AstraZeneca | 1 | $43 |
| Genentech, Inc. | 1 | $34 |
| Spark Therapeutics, Inc. | 1 | $19 |
| Carl Zeiss Meditec USA, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$48,898 in reported general payments places this provider in the 90th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Phoenix
- Ramin SchadluPhoenix$1.8M
- John CasonPhoenix$1.7M
- Benjamin HellerPhoenix$1.1M
- Neal PalejwalaPhoenix$627K
- Pravin DugelPhoenix$479K
- Robert GrossPhoenix$268K
- Sujit IttyPhoenix$216K
- Jung DaoPhoenix$213K
- Karim JamalPhoenix$101K
- Nishi ShahPhoenix$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.